Company News – Tue 18 Apr, 2017

Theralase PDT Technology Used to Treat Second Patient for Bladder Cancer

Below is the news on that the second patient has been treated for bladder cancer in the Theralase Phase 1b clinical study. Roger Dumoulin-White, President and CEO of Theralase outlined that this patient and one additional were scheduled in our last interview (click here for the most recent interview). Now that the second patient has been treated and the third is scheduled we will have to wait 30 days as the paitnets are monitored. Read the full release below for all the details.

Also, the Company issued 2,800,000 stock options to directors and officers that vest over 3 years and expire in 5. These options carry an exercise price of $0.50. click here for that full news release.

Here is the news on the second patient…

Toronto, Ontario – April 18, 2017, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the second patient was treated on April 12, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology.

The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.

The Phase Ib NMIBC clinical study (“Study”) will be used to evaluate TLD-1433 for the primary endpoints of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.

The Study has been designed to treat 3 patients at a lower dose of the PDC and to monitor the patients for 30 days, according to the endpoint criteria above. If successful, then an additional 6 patients will be enrolled into the Study to be treated at a higher dose of the PDC and monitored for 180 days, according to the endpoint criteria.

The next patient in the Study has been enrolled and is currently scheduled for treatment.

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase has now completed PDT treatment of 2 patients and looks forward to successfully treating the next patient and reporting out on the status of the first three patients in the Study in 2Q2017.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investor s should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225

rwhite@theralase.com

www.theralase.com


Featuring:
Roger White
View related posts on: ,

Comments:
  1. On April 18, 2017 at 11:00 am,
    Ulf says:

    And no love whatsoever from the markets. It’s a strange world. I wonder how much info, if any, they will give us on that CT scan after the first 30 days? Oh, well, I guess we will see.

    • On April 18, 2017 at 11:09 am,
      David says:

      Share price drop might be the management warrants in the release. Although the option price is .50 and above market, they are also potentially dilutive. Hopefully they will be offset with progress in the human trials. So far so good.

  2. On April 18, 2017 at 11:11 am,
    Ulf says:

    Buying my last batch tomorrow 🙂 I think i have said that a few times now. But if there ever is a time to take a bet with good attached to them, this is it.
    I wonder when we trade on Nasdaq?

  3. On April 18, 2017 at 4:06 pm,
    Jason says:

    Why is all this news not getting posted to Scottrade and other brokerages? Stock was down today. My position was down 2/3s.

  4. On April 20, 2017 at 9:09 am,
    Ulf says:

    And now the third patient is treated.

  5. On April 22, 2017 at 2:29 am,
    Mildred says:

    Tremendous issues here. I’m very happy to look your article.
    Thanks so much and I’m taking a look ahead to touch you.
    Will you please drop me a e-mail?
    Real Madrid Modric Hemmaställ